Medical Devices - San Marcos, California, United States
INNOVATIVE HOME USE DEVICEAllergia has successfully designed, patented and tested a home-use medical device that uses phototherapeutics to suppress the symptoms of seasonal allergenic rhinitis (hay fever). It has the potential to disrupt the $7.6 billion nasal allergy market.SUPERIOR TO CURRENT TREATMENT OPTIONS. Allergia will provide an efficient, safe, inexpensive and easy-to-use device, compared to current drug treatments, such as antihistamine, intranasal corticosteroids, and immunotherapy.EXCELLENT CLINICAL RESULTS. IRB- sanctioned Pilot Study: 31% improvement in Total Nasal Symptom Score (TNSS) v. Baseline ( p = 0.013 ) - compared with a 22% improvement for nasal antihistamines.NO SIDE EFFECTS. No side effects. No drowsiness. High satisfaction of users of the device.Large & Growing Addressable Market. 95M seasonal allergy sufferers in US, EU and Japan. 46.8M prescriptions filled for nasal allergy treatments. Market is dominated by major pharmaceuticals: $1.8B in sales from top ten OTC allergy brands. GO-TO-MARKET DRIVERS. An efficient, safe, inexpensive and easy-to-use, convenient device. Superior to current drug treatments. Higher efficacy than antihistamines, with no side-effects, no drowsiness, no contra-indications. Growing demand for non-pharmaceutical solutions. Allergia would be the only FDA-approved phototherapeutic device in the U.S. Market.MILESTONES. Successful Pilot Study. Patent. Favorable responses from FDA Pre-submission.TECHNOLOGY. Uses broadband Red Light (proven completely safe) - therapeutic window is 600-800nm. The Allergia device is the only platform capable of delivering light with the requisite intensity and quality to render a home-use hand-held device efficacious and marketable. Results from Pilot Study are consistent with growing body of research demonstrating the efficacy and safety of phototherapy in managing allergic rhinitis.
Gmail
Google AdSense
Mobile Friendly
Google Cloud Hosting